Myriad kept by JMP at market outperform

Myriad Genetics Inc. was maintained by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $25 per share following news that its phase III trial enrollment for Flurizan to treat Alzheimer's was going well, the time line is preserved for approval and signs of less risk of clinical failure. Myriad Genetics shares Tuesday gained $0.25, or 1.43%, to close at $17.77 on volume of 237,072 shares versus the three-month running average of 400,945 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.